Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-7

Ynkforever, hold my beer, I got this.

It’s clear some people’s positivity in lbt as a med-tech specie hasn't changed.

There’s risk, lot's of it, and likewise its upside is potentially lot's, lots and lots.

Obv only a fraction of these sort of new companies get up, and everything we've seen so far including the dragged out timeline has been seen somewhere else in another med tech specie time and time again.

All I can say is if I had half the concerns of the vocal minority on hc regarding management, I'd simply have the courage of my convictions and sell my holdings and be on my way. I don't care for sunk costs.

Either way, good question, I’m glad we don’t suppress differing opinions here.

Glad some are positive.

In my opinion, forget the share price, look at the business, if today is day zero and you look at the company, it's product, it's distribution, it's management, upcoming potential sales, and then also take into consideration it's falls into the specie category...... and you then believe it's a opportunity, than it's a good buy.

If not, in my opinion I’d ask myself, why am I holding at all ?
I don’t believe in sunk costs.

As Ynkforever would say…GLTAH legends 50 bagger in five years or bust